Aligos Therapeutics Inc.

20.60-0.7400-3.47%Vol 26.64K1Y Perf 36.97%
Apr 13th, 2021 16:00 DELAYED
BID20.54 ASK20.66
Open21.28 Previous Close21.34
Pre-Market- After-Market-
 - -%  - -
Target Price
35.75 
Analyst Rating
— — 0.00
Potential %
72.79 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap785.75M 
Earnings Rating
Price Range Ratio 52W %
31.51 
Earnings Date
-

Today's Price Range

20.0921.64

52W Range

12.8237.51

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.83%
1 Month
-18.36%
3 Months
-36.05%
6 Months
-
1 Year
36.97%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALGS20.60-0.7400-3.47
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.492.58001.01
XOM55.700.20000.36
WFC39.77-1.0000-2.45
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.90-1.09-21.11
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume26.64K
Shares Outstanding38.14M
Trades Count623
Dollar Volume2.18M
Avg. Volume69.92K
Avg. Weekly Volume37.59K
Avg. Monthly Volume56.87K
Avg. Quarterly Volume68.03K

Aligos Therapeutics Inc. (NASDAQ: ALGS) stock closed at 21.34 per share at the end of the most recent trading day (a -0.61% change compared to the prior day closing price) with a volume of 45.47K shares and market capitalization of 785.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Aligos Therapeutics Inc. CEO is Lawrence M. Blatt.

The one-year performance of Aligos Therapeutics Inc. stock is 36.97%, while year-to-date (YTD) performance is -22.82%. ALGS stock has a five-year performance of %. Its 52-week range is between 12.82 and 37.51, which gives ALGS stock a 52-week price range ratio of 31.51%

Aligos Therapeutics Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 3.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.10%, a ROC of -54.58% and a ROE of -145.32%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aligos Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aligos Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aligos Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aligos Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aligos Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aligos Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.03, ATR14 : 3.15, CCI20 : -28.92, Chaikin Money Flow : 0.01, MACD : -1.24, Money Flow Index : 66.60, ROC : 11.15, RSI : 45.62, STOCH (14,3) : 66.30, STOCH RSI : 0.97, UO : 46.42, Williams %R : -33.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aligos Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

CEO: Lawrence M. Blatt

Telephone: +1 800 466-6059

Address: One Corporate Drive, South San Francisco 94080, CA, US

Number of employees: 73

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

86%14%

Bearish Bullish

70%30%

News

Stocktwits